Results. In both treated groups, caspase-3 activity was inhibapoptosis causes cell deletion that affects renal function ited, and 17 and 24 kD active caspase-3 proteins were reduced and remodeling [4] [5] [6] [7] . Therefore, the control of apoptosignificantly. A compensatory increase of caspase-3 mRNA ocsis and its mediators could be a potential target for theracurred in the acutely treated group, but decreased in the chronipeutic interventions manipulating both the early inflamcally treated group (P Ͻ 0.05). Although there were no signifimation as well as the late atrophic and fibrotic changes cant changes in caspase-1 activity and its active protein, the observed decrease in its precursor in the chronic group was in progressive glomerulonephritis. increased by treatment (P Ͻ 0.05). Further, IL-1␤ precursor Although different signals initiate apoptosis, the pheand its mRNA were significantly reduced by treatment only notype of apoptosis is surprisingly similar even in differin the chronically treated group. Apoptosis was decreased in ent cell types, suggesting that the final stage of apoptotic the glomeruli of acutely treated rats, and in the tubules and death is highly conserved [8] . A class of cysteine proteinterstitium of chronically treated animals (P Ͻ 0.05). Glomerular inflammation was decreased only in the acutely treated ases (caspase family, 14 different members) coordinates group, whereas tubulointerstitial inflammation was lowered in the execution of the death program. In particular, casboth treated groups (P Ͻ 0.05). Glomerulosclerosis was repase-3 is a major execution enzyme acting upstream of duced in both inhibitor groups, with a reduction in tubulointeractivated via an endoplasmic reticulum (ER) pathway (through caspase-12) [12] .
Apart from the promotion of apoptotic cell death, during the course of experimental GN. We observed a significantly protective effect by the inhibition of caspase the caspase family of enzymes also participates in the processing of proinflammatory cytokines [13, 14] . Cas-enzymatic pathway on renal cell apoptosis, inflammation and fibrosis, while also partially improving functional pase-1 [interleukin (IL)-1␤-converting enzyme (ICE)] is the pro-IL-1␤ processing enzyme [15] . IL-1␤, a cytokine parameter. with a wide range of proinflammatory actions, is increased in the kidneys of rat antiglomerular basement METHODS membrane (GBM)-mediated glomerulonephritis [neph-Nephrotoxic serum nephritis rotoxic nephritis (NTN)] and plays an important role in crescent formation and tubulointerstitial injury [16] .
Glomerulonephritis was induced in male Wistar Kyoto rats weighing 200 to 300 g with a single injection of 0.5 Early and late treatment with an IL-1 receptor antagonist prevents and suppresses the progression of crescentic mL of rabbit antirat GBM serum into the tail vein [7] . B-D-FMK (316.5 g/24 hours) (Enzyme Systems Prod-glomerulonephritis in this model [17, 18] . Caspase-1 knockout mice treated with lipopolysaccharide have a ucts, Livermore, CA, USA) or drug vehicle [dimethyl sulfoxide (DMSO)] (Sigma, Dorset, UK) was adminis-blunted IL-1␤ response [15] and demonstrate reduced ischemic brain injury [19] .
tered by intrarenal delivery [30] using a fenestrated cannula attached to subcutaneous Alzert osmotic mini-Caspase inhibitors, including peptide-based inhibitors of caspase, are highly effective in preventing apoptotic pump (Charles River Ltd., Kent, UK). The dose of B-D-FMK was calculated on the basis that it appears to be the cell death in in vitro models of apoptosis [20, 21] . The investigation of caspase-3-deficient mice has suggested that minimum dose required for maximum caspase inhibitory effect in renal cell culture (Abstract; Yang et al, J Am this enzyme may be an appropriate target for therapeutic interventions in diseases resulting from inappropriate Soc Nephrol 11:A2468, 2000) and the significant effect observed in a pilot in vivo study as well as the order of apoptosis [22] . For example, the elevated apoptosis in hepatic parenchymal cells induced by tumor necrosis magnitude of other drugs administered by this method in our laboratory [30] . B-D-FMK or DMSO was adminis-factor-␣ (TNF-␣)-mediated endotoxemia was prevented by benzyloxycarbonyl-Val-Ala-Asp (OMe) (ZVAD), tered to rats on two time schedules. The first started one day before the induction of NTN and continued for 7 providing a caspase-3 inhibition, which reduced the severity of the disease [23]. In addition, the administration days (acutely). The second started 15 days after NTN and continued for 28 days (chronically). The acutely of Boc-Asp (OMe)-fluoro-methyl-ketone (B-D-FMK) after cerebral hypoxia/ischemia, inhibited caspase-3 ac-treated group was designed to observe the effects on caspase-3 inhibition on the inflammatory reaction while tivity and was neuroprotective [24] . More recently, it has been reported that ZVAD-FMK reduced the caspase-3 the chronically treated group was intended to allow the evaluation of chronic scarring phase. Rats were injected activity and prevented the early onset of not only renal apoptosis, but also inflammation and tissue injury in a with normal rabbit serum and received DMSO as controls for both time points (each experimental group con-mouse model of renal ischemia/reperfusion [25] .
Previous studies have demonstrated the increase of cas-sisted of six to eight rats). Rats were killed at the end of the experiment. Kidneys were removed and quartered. pase-3 in various experimental models of renal disease, including ischemic renal injury [26] and cyclosporin One quarter was fixed in 10% (wt/vol) neutral buffered formalin and another in 2.5% (vol/vol) glutaraldehyde A-induced nephrotoxicity [27] . Our work has highlighted the importance of apoptosis in the development for histologic, immunohistochemical, and electron microscopic examination. The remaining tissue was snap-of glomerulosclerosis and tubular atrophy [28] , where up-regulation of caspase-3 activity, protein, and synthesis frozen and stored in liquid nitrogen for activity, protein, and mRNA analyses. Serum creatinine (standard auto-has been described in both the subtotal nephrectomy (SNx) [7] and NTN [29] models of experimental renal analyser techniques) and 24-hour urinary protein (Lowry method) were measured at sacrifice. Rats were housed scarring. Given these findings, a similar blockade of caspase-3 in progressive renal scarring may provide a novel at constant temperature and humidity on a 12-hour light/ dark cycle and fed ad libitum on standard rat chow. All means to the treatment of renal scarring by controlling inappropriate apoptosis. Therefore, in this study, we procedures were carried out according to the regulations laid down by the Home Office (Animal Scientific Proce-have applied a cell-permeable pan caspase inhibitor, B-D-FMK, to rats with progressive NTN in order to dure Act 1986, UK). block the activity of caspases (predominantly caspase-3, Detection of tissue caspase-3 and caspase-1 activity but also significantly caspases 1, 8, 9, and 12) and subsequent apoptotic cell death. We have determined the ef-Caspase-3 or caspase-1 activity was detected by the modified Fluorometric CaspACE TM Assay System (Pro-fects of caspase inhibition on the early inflammatory/apoptotic changes and the late apoptotic/sclerotic changes mega, Southampton, UK) using 100 g of protein ex-tracted from renal tissue [7] . This assay is based on the sodium phosphate and 7% (wt/vol) sodium dodecyl sulfate (SDS)] at 65ЊC [7, 36] . The filter was exposed to ability of caspase-3 or 1 to cleave the fluorogenic substrate of either Ac-DEVD-amino-4-methyl coumarin Kodak Biomax MS film (Sigma) for 24 to 48 hours. Autoradiographs were semiquantitatively analyzed by (AMC) or Ac-YVAD-AMC. The specificity of the assay was determined using the caspase-3 or 1 inhibitor Ac-scanning volume density using a Bio-Rad GS-690 densitometer and Molecular Analyst version 4 software. Vol-DEVD-CHO or Ac-YVAD-CHO. The proteolytic cleavage of substrates was monitored in a fluorescence mi-ume density was corrected for loading using the housekeeping gene cyclophilin [7] , which remained stable croplate reader (SOFTmax PRO, Molecular Devices Corp., Sunnyvale, CA). The fluorescence intensity was during the experiment. Results were expressed as the percentage of the average controls' mRNA volume den-calibrated with standard concentrations of AMC and caspase-3 or caspase-1 activity was expressed as pmol sities. Transcript size was determined by comparison to RNA molecular weight markers (Promega) using the AMC liberated per minute per g protein at 30ЊC. same analysis package and by visual comparison to the Measurement of tissue caspase-3, caspase-1, and IL-1␤ ribosomal RNA subunits.
protein by Western blot
In situ end labeling (ISEL) of apoptotic cells Twenty g of protein [20% (wt/vol) homogenate] was separated on a 15% (wt/vol) polyacrylamide denaturing Using paraffin sections, fragmented nuclear DNA associated with apoptosis was labeled in situ with digoxi-gel and electro-blotted onto Hybond-C membrane (Amersham Life Science, Buckinghamshire, UK). This was genin-deoxyuridine (dUTP) by terminal deoxynucleotidyl transferase (TdT) using the ApopTag Plus peroxidase blocked with 3% (wt/vol) bovine serum albumin (BSA) and probed with a polyclonal rabbit antirat full-length kit (Appligene Oncor, Illkirch, France) [28, 37] . For each experimental animal, more than 30 glomerular cross-caspase-3 (Santa Cruz Biochemicals, Santa Cruz, CA, USA), caspase-1 (Upstate Biotechnology, Milton Keynes, sections and 20 high-power (ϫ400 magnification) fields of tubulointerstitium were examined blinded to the ex-UK), and IL-1␤ (NIBSC, Potters Bar, UK) antibodies at 1:1,000, 1:500, and 1:1000 dilution, respectively. The perimental code by two of the authors (B. Yang and A.M. El Nahas). In situ end labeling (ISEL) ϩ nuclei antibody binding was revealed using an antirabbit peroxidase conjugate (Dako, Glostrup, Denmark) or the ABC per glomerulus, per 400 tubular cells, and per interstitial field were determined, respectively. To substantiate the Elite Kit (Vector Laboratories, Peterborough, UK) diluted at 1:1,000 and the ECL chemiluminescent detection specificity of our results, we confirmed apoptosis by light and electron microscopy to evaluate the morphologic system (Amersham Life Science). Developed films were semiquantitatively analyzed by scanning volume density features; only strongly positive ISEL cells with observable morphologic features of apoptosis such as shrunken using a Bio-Rad GS-690 densitometer and Molecular Analyst version 4 software (Bio-Rad Laboratories, Ltd., cells with condensed nuclei were counted [38, 39] . Herts, UK). Results were expressed as the percentage of Evaluation of inflammation by ED-1 immunostaining the average controls' mRNA volume densities. Translation size was determined by comparison to protein mo-Cellular inflammation was evaluated by ED-1 (a specific rat monocyte/macrophage marker) immunostaining lecular weight markers (Bio-Rad Laboratories, Ltd.) using the same analysis package.
on paraffin sections using a standard avidin-biotin peroxidase complex technique [40] . The sections were pre-Northern blot analysis of caspase-3, IL-1␤, collagen I, treated with 0.125% (wt/vol) trypsin and incubated with III, and IV mRNA the primary antibody (monoclonal mouse antirat ED-1 antibody, Serotec Ltd., Oxford, UK) at 1:50 dilution or Fifteen g of total RNA extracted using TRIzol reagent (Life Technologies BRL, Paisley, UK) were elec-normal mouse immunoglobulin G (IgG) at the same protein concentration of primary antibody as negative trophoresed on a 1% (wt/vol) agarose/3-(N-Morpholino) propanesulfonic acid (MOPS)/formaldehyde gel, capil-control. The antibody binding was revealed using the ABC Elite Kit (Vector Laboratories, Peterborough, lary blotted onto Hybond-N membrane (Amersham Life Science) and crosslinked with 70 mJ/cm 2 radiation (UV UK) and 3Ј-amino-9-ethylcarbazole substrate. ED-1ϩ cells in glomeruli and interstitium were semiquantita-Crosslinker, Amersham Life Science) [31] . This was then probed with 32 P-labeled deoxycytidimine triphosphate tively assessed by the same counting system as described above for ISEL. (dCTP) random primed DNA probes. Specific random primed DNA probes were constructed from the follow-Estimation of renal scarring ing sequences: rat caspase-3 [26] , IL-1␤ [32] , human collagen ␣1 (I) [33] , rat collagen ␣1 (III) [34] and human
The extent of renal scarring was semi-quantitatively analyzed on Masson's Trichrome (MT)-stained sections collagen ␣1 (IV) [35] . Prehybridization and hybridization were performed using the Church buffer system [0.5 mol/L at ϫ200 magnification. Two authors (B. Yang and A.M.
El Nahas) blinded to the experimental code scored the 0.05). These caspase-3 subunits were diminished in the NTN kidneys treated with B-D-FMK in acute (Ϫ61% severity of glomerular injury/sclerosis, tubular atrophy, for both, P Ͻ 0.05) and chronic (Ϫ46% for 17 kD and and tubulointerstitial fibrosis, according to a previously Ϫ37% for 24 kD, P Ͻ 0.05) experiments. The 32 kD published arbitrary scale (from 0 to 3) [41] . Scores were band, precursor of caspase-3, increased by ϩ392% (P Ͻ attributed as following: a normal glomerulus scored 0; 0.05) only in the chronically untreated NTN kidneys, mild glomerular sclerosis affecting up to 25% of glomerwhich was reduced by Ϫ38% (P Ͻ 0.01) after B-D-FMK ular tuft scored 1; moderate glomerular sclerosis affecttreatment. The 29 kD processing intermediate was also ing between 25% and 50% of tuft scored 2; and severe present in the kidneys of all groups (Fig. 1B ). glomerular sclerosis affecting in excess of 50% of tuft
We performed Northern blot analysis on kidney tisscored 3. Tubulointerstitial scarring was defined and scored sues to address whether B-D-FMK affected caspase-3 as normal tubules with tubular cell number (TCN) aptranscription. In the acute group, the 2.7 kb caspase-3 proximately 1000 and no expansion of interstitium scored mRNA transcript (Fig. 1C ) was increased by ϩ250% in 0; mild tubular atrophy with TCN approximately 800 the untreated NTN kidneys in comparison to controls, and interstitial edema or fibrosis (IF) affecting up to which was further increased by ϩ139% in the NTN kid-25% of the field scored 1; moderate tubular atrophy with neys treated with B-D-FMK (P Ͻ 0.05). In the chronic TCN approximately 600 and IF affecting 25% to 50% study, caspase-3 mRNA was increased by ϩ566% in the of the field scored 2; and severe tubular atrophy with untreated NTN kidneys, but decreased by Ϫ52% (P Ͻ TCN approximately 400, IF exceeding 50% of the field 0.01) in the NTN kidneys treated with B-D-FMK (P Ͻ scored 3. The data were collected from a series of adja-0.05) ( Fig. 1C ). cent fields extending perpendicularly from the cortex toward the outer medulla. Three such randomly selected
Effect of B-D-FMK on caspase-1 activity and proteins linear series of minimum12 fields were measured in the
There was no significant change in renal caspase-1 cortex or such number of fields until 30 glomeruli had activity (pmol AMC liberated per minute per g protein been counted per section.
at 30ЊC) between experimental groups ( Fig. 2A ). Of note, the competitive tetrapeptide inhibitor, Ac-YVAD-Statistical analysis CHO, inhibited the activity of caspase-1 only about Results are expressed as mean Ϯ standard error of 65.5% in the in vitro assay. the mean (SEM). The statistical difference was assessed
The expression of caspase-1 proteins was detected by Western blotting analysis. The active subunit of caspase-1, by a single factor variance (ANOVA) or Student t test.
a 20 kD band, remained unchanged through both the P Ͻ 0.05 was considered to be significant. acute and chronic time courses and was not affected by B-D-FMK ( Fig. 2B ). However, the precursor of caspase-1, RESULTS a 45 kD band, was significantly decreased by Ϫ40% in Effect of B-D-FMK on caspase-3 activity, proteins, chronic NTN kidneys and increased again by ϩ18% after and mRNA the treatment with B-D-FMK (P Ͻ 0.05) ( Fig. 2B ). Caspase-3 activity (pmol AMC liberated per minute B-D-FMK reduced IL-1␤ proteins and synthesis in per g protein at 30ЊC) was increased in the early (0.059 Ϯ NTN kidneys 0.005) and late (0.084 Ϯ 0.009) untreated (DMSO/vehicle-Although no significant changes in caspase-1 activity infused) NTN kidneys compared to their controls (0.021 Ϯ and the active subunit of caspase-1 were seen, the expres-0.004 and 0.027 Ϯ 0.005, respectively, P Ͻ 0.01). This sion of the caspase-1 precursor was reduced and corelevated caspase-3 activity was reduced in the NTN kidrected by B-D-FMK. Therefore, we further investigated neys treated with B-D-FMK in both acute (Ϫ40%, P Ͻ whether B-D-FMK had an effect on IL-1␤ at both pro-0.01) and chronic (Ϫ29%, P Ͻ 0.05, Figure 1A ) treattein and mRNA levels, as pro-IL-1␤ may be processed ment groups. The specific and competitive tetrapeptide by either caspase-1, caspase-3 (caspase-1 independent), inhibitor of caspase-3, Ac-DEVD-CHO, almost fully inor both pathways [42] . hibited the caspase-3 activity in the assays, demonstra-IL-1␤ proteins in kidney tissues were determined by ting the specificity of the assay. In the noncannulated Western blotting analysis. The 17 kD band representing contralateral NTN kidneys, caspase-3 activity was also the IL-1␤ active subunit was increased in the acutely significantly reduced to a similar level of the treated (ϩ223%) and chronically (ϩ169%) untreated NTN kidkidneys suggesting a systemic effect (data not shown).
neys (P Ͻ 0.05). This IL-1␤ subunit was reduced in the Caspase-3 proteins in kidney tissues, determined by NTN kidneys treated with B-D-FMK of both groups, Western blotting analysis, showed that 17 kD and 24 kD but did not reach statistical significance (Ϫ46% and bands, representing caspase-3 active subunits, were in-Ϫ42%, P Ͼ 0.05). The 35 kD band, precursor of IL-1␤, creased in the acutely (ϩ292% and ϩ296%) and chroniincreased by ϩ249% and ϩ181% (P Ͻ 0.05) in both acutely and chronically untreated NTN kidneys, which cally (ϩ361% and ϩ265%) untreated NTN kidneys (P Ͻ remained at a similar level in the acute group and was the chronic investigation, the expression of IL-1␤ mRNA was significantly increased by ϩ270% in the untreated reduced by Ϫ66% (P Ͻ 0.01) in the chronic group after B-D-FMK treatment (Fig. 3A) .
NTN kidneys, which was subsequently decreased by Ϫ59% in the NTN kidneys treated with B-D-FMK (P Ͻ In the acute study, there was no significant change in the expression of the 1.6 kb IL-1␤ mRNA (Fig. 3B ). In 0.05, Fig. 3B ). 
Apoptotic changes following B-D-FMK administration Fibrotic and functional changes after B-D-FMK treatment Apoptotic cells were detected by ISEL of fragmented
The extent of glomerular sclerosis, tubular atrophy, DNA. Positively stained cells were counted and conand tubulointerstitial fibrosis were semiquantitatively firmed by distinct morphologic motifs using light and analyzed on the MT-stained sections. Glomerular scleroelectron microscopy. Very few apoptotic cells were noted sis was severe and progressive in the untreated NTN in the glomeruli (0.012 Ϯ 0.009/glomerulus), tubules kidneys ( Fig. 7 a and e, acute; c and g, chronic) . This (0.026 Ϯ 0.008/400 tubular cells) and interstitium (0.057 Ϯ was reduced by Ϫ27% ( Fig. 7 b and f, acute) and Ϫ31% 0.014/ϫ400 field) of control kidneys (Fig. 6A ). In the ( Fig. 7 d and h, chronic) in NTN kidneys treated with acute study, apoptotic cells in glomeruli (0.467 Ϯ 0.073/ B-D-FMK for both time periods ( Fig. 7i , P Ͻ 0.05). No glomerulus) were increased in untreated NTN kidneys significant difference in tubular atrophy or tubulointers-( Fig. 4a and aЈ) compared with controls (P Ͻ 0.01). This tial fibrosis was noted in the early (acutely) untreated was decreased by Ϫ55% (P Ͻ 0.01) in the NTN kidneys and treated NTN kidneys ( Fig. 7 a, b , and i) compared treated with B-D-FMK ( Figs. 4b and 6A ). In the chronic to controls (TCN, 960.0 Ϯ 8.2 tubular cell/ϫ200 field). group, apoptotic cells in glomeruli were also higher in
In the chronic study, tubular atrophy (TCN, 570.0 Ϯ 31.3 untreated NTN kidneys (P Ͻ 0.05), and were not affected tubular cell/ϫ200 field, P Ͻ 0.01) and tubulointerstitial by B-D-FMK treatment. Apoptotic cells in tubules fibrosis ( Fig. 7 c, g, and i) were increased in the untreated (1.112 Ϯ 0.238/ϫ400 tubular cells) and interstitium NTN kidneys compared to controls (TCN, 952.5 Ϯ 8.54 (0.680 Ϯ 0.072/ϫ400 field) were also increased in the tubular cell/ϫ200 field). Caspase inhibition significantly untreated NTN kidneys (P Ͻ 0.01, Fig. 4c ); however, improved tubular atrophy (TCN, 714.00 Ϯ 39.32 tubular this was significantly decreased by Ϫ64% (P Ͻ 0.05) and cell/ϫ200 field, P Ͻ 0.05) and reduced tubulointerstitial fibrosis by Ϫ34% ( Fig. 7 d, h , and i). Ϫ57% (P Ͻ 0.01), respectively, in the B-D-FMK-treated These results were supported by the assay of tissue NTN kidneys ( Fig. 4d and 6A) . In both groups, the areas collagen I, III, and IV mRNA using Northern blot analymostly contained apoptotic cells were the inflamed or sis. In the acute study, the 4.8 kb/5.8 kb of collagen I sclerotic glomeruli (Fig. 4e) as well as the dilated or mRNA was increased by ϩ220% in the untreated NTN atrophied tubules ( Fig. 4f ) and expanded interstitium kidneys, and further increased to ϩ480% (P Ͻ 0.05) in (Fig. 4g ). Electron microscopy confirmed apoptotic cells the NTN kidneys treated with B-D-FMK. There was no with distinct morphological motifs in some glomeruli significant change in the expression of 5.4 kb collagen (not shown), tubules ( Fig. 4h ) and interstitium ( Fig. 4i ). III and 6.5 kb/4.5 kb collagen IV mRNA transcripts in the acute study. In the chronic study, the expression of Inflammatory (ED-1ϩ) changes following B-D-FMK collagen I, III and IV mRNAs increased by ϩ1487%, administration in NTN kidneys ϩ522% and ϩ442% in the untreated NTN kidneys and Inflammatory monocytic infiltration of the kidneys were decreased by Ϫ63%, Ϫ58% and Ϫ72% in the was evaluated by immunostaining of ED-1. A small numtreated kidneys (P Ͻ 0.05, Fig. 7j to l). ber of ED-1ϩ cells were seen in the glomeruli (0.22 Ϯ There was no detectable change in the body and kid-0.01/glomerulus) and interstitium (1.02 Ϯ 0.12/ϫ400 ney weight or serum creatinine among groups in the field) of control kidneys (Fig. 6B ). Over the first 7 days, acute study (Table 1 ). In the chronic study, kidney weight ED-1ϩ cells were increased in the glomeruli (20.61 Ϯ and serum creatinine, but not body weight, were signifi-1.71/glomerulus) and interstitium (18.91 Ϯ 1.20/ϫ400 cant increased in the untreated rats. However, neither was affected by B-D-FMK treatment (Table 1) . Proteinfield) of untreated NTN kidneys (P Ͻ 0.01). This was uria was significantly increased in both early and late decreased by Ϫ27% (P Ͻ 0.01) in the glomeruli and by untreated NTN rats (113.45 Ϯ 13.18 and 399 Ϯ 33.33 mg/ Ϫ22% (P Ͻ 0.05) in the interstitium following B-D-FMK 24 hours) compared to controls (P Ͻ 0.01). Of note, treatment. In the chronic experiment, ED-1ϩ cells in NTN kidneys treated with B-D-FMK both acutely the glomeruli (7.51 Ϯ 1.39/glomerulus) were less than in (Ϫ38%) and chronically (Ϫ29%) had a significant reducthe acutely untreated NTN kidneys but still significantly tion of proteinuria (P Ͻ 0.05, Table 1 ). higher than controls. No significant change was noted after B-D-FMK treatment. In the interstitium of the late untreated NTN kidneys, ED-1ϩ cells (34.57 Ϯ 3.15/ϫ400 DISCUSSION field) were almost double that on the normal, but re-Apoptosis has a critical role in the resolution of induced by Ϫ53% (P Ͻ 0.01) in those receiving B-D-FMK flammatory response, such as that occurring in glomerutreatment (Fig. 6B) . Positive ED-1 cells were distributed lonephritis [2, 3]. However, if the induction of apoptosis in the inflamed glomeruli ( Fig. 5 a, b , e, and f), interstibecomes uncontrolled, it leads to glomerular and tubular cell deletion, and glomerular sclerosis as well as tubular tium and tubular lumen ( Fig. 5 c, d, g, and h ). (a, b, and e ), tubules (c, d, and f ) and interstitium (g ) at ϫ200 (a to d) and ϫ400 (e to g) magnification. Typical morphologic changes of apoptosis such as a shrunken cell with condensed nuclei surrounded by narrow cytoplasmic halo is shown in an enlarged picture of a glomerular apoptotic cell (a). Using electron microscopy, apoptotic cell phagocytosed by tubular cell (h, ϫ6858) and apoptotic cell in interstitium are shown (i, ϫ6858). ᭣ atrophy and interstitial fibrosis subsequently ensued in caspase-3 activity in the infused and contralateral kidneys of both acute and chronic experimental groups. This [5, 7] . In previous experiments on rats with NTN and SNx, we have observed the progressive glomerular and indicated that the local delivery of B-D-FMK for 7 or 28 days had a systemic effect. It also led to a decrease tubular cell apoptosis and postulated that renal cellular apoptosis contributed to glomerulosclerosis and tubular of caspase-3 protein levels in renal tissues. More interestingly, this decrease was despite an early up-regulation atrophy [7, 28] . In these studies, a strong association was noted between the up-regulation of caspase-3, the of caspase-3 transcription as a compensatory reaction to the inhibition of this enzyme, which declined later in the occurrence of apoptosis, and the progression of scarring/ fibrosis [7, 29] . Recent evidence linking caspase-3 and experimental time course. These changes may reflect the effect of autoadjustment to the caspase enzyme inhibitor inflammation indicates that caspase-3 may also play a role in the inflammatory changes that characterize early at mRNA level in this in vivo model. All these results indicate that the caspase-3 activity, proteins, and mRNA glomerulonephritis, as well as the late interstitial inflammation, which precedes renal fibrosis in progressive were affected by B-D-FMK. In other words, the action of B-D-FMK on apoptosis and inflammation during the glomerulonephritis [7, 25] . The pivotal role of caspase-3 in the machinery of apoptosis and inflammation makes course of NTN may be predominantly through the inhibition of caspase-3. it as an attractive target to regulate the progression of glomerulonephritis and renal fibrosis.
Posttranslation, caspase-3 can be activated through three pathways. First, caspase-3 activation may be medi-In this study, we have used the intrarenal administration of a cell-permeable pan caspase inhibitor, B-D-FMK, to ated by death receptors, such as (Fas/FasL system), which is associated with the activation of caspase-8. Sec-test the effect of caspase inhibition on both apoptosis and inflammation, and the ensuing renal scarring in the ond, caspase-3 activation may also be mediated by the mitochondria (through Bax/Bcl-2) with release of cyto-in vivo rat NTN model. The administration of B-D-FMK in the acute phase (starting 1 day before NTN and lasting chrome c, which is required for caspase-9 activation [10, 44, 45] . Third, caspase-3 can be activated by caspase-12 7 days) of NTN prevented the early onset of glomerular apoptosis and inflammation. In addition, the early inhibi-when the ER is under stress [12] . Auto-or transactivation of initiator caspase-8, caspase-9, and caspase-12 results tion of caspase also blunted tubulointerstitial inflammation. These effects may have contributed to the attenua-in the subsequent cleavage and activation of the downstream effector caspase-3 [10]. B-D-FMK is a pan cas-tion of glomerular injury and proteinuria. Conversely, when B-D-FMK was administered chronically starting pase inhibitor and was assumed to have a role on all caspases, including caspase-8, caspase-9, and caspase-12. on day 15 after the induction of NTN and continuing for 28 days, it predominantly ameliorated the tubular Therefore, B-D-FMK not only directly inhibited the activity of caspase-3 (demonstrated by the caspase-3 activ-apoptosis, interstitial inflammation, and fibrosis. It also reduced glomerulosclerosis and proteinuria. These re-ity assay), but also prevented the formation of active caspase-3 (showed by the expression of caspase-3 pro-sults indicate that this pan caspase inhibitor has a potential not only to prevent, but also to halt, the progression teins) by possibly causing a reduction in the activity of caspase-8, caspase-9, or caspase-12. So the effects of of glomerulosclerosis and interstitial fibrosis [43] .
In order to evaluate the protective mechanisms of B-D-FMK on apoptosis and inflammation may be attributed to the inhibition of both caspase-3 activity and acti-B-D-FMK in renal injury, we detected the expression of caspase-3 at activity, protein and mRNA levels in renal vation. Further, we cannot rule out a role for B-D-FMK on other caspases, such as caspase-6 and caspase-7 (an-tissues. Caspase-3 is a key enzyme in the apoptotic process and is also involved in the progression of inflamma-other two effector caspases), which could be the subject of future studies. tion [11, 25] . Application of B-D-FMK led to a decrease ᭣ Fig. 5. Renal Inflammation evaluated by ED1 staining. ED1ϩ cells in glomeruli (a, b, e, and f ) and interstitium (c, d, g, and h ) at ϫ100 (a to d) and ϫ200 (e to h) magnification. The appearance of apoptosis is closely correlated with could happen when the apoptotic inflammatory cells did not be cleared away in time. While initial reports dissoci-the increase of caspase-3 activity, as shown in our previous study in this experimental model of accelerated glo-ated apoptosis from inflammation, a growing body of experimental evidence links the two, which was clearly merulonephritis [7] . In the present investigation, B-D-FMK with caspase-3 inhibition decreased the occurrence of demonstrated following renal ischemia/reperfusion injury [25] . On the other hand, we have expected that the apoptosis as revealed by the decreased number of ISELpositive nuclei. The inhibition of apoptosis occurred inhibition of apoptosis in the acute phase of glomerulonephritis would have led to diminish the resolution of early in the glomeruli mainly after an acute administration of B-D-FMK for 7 days and late predominantly in acute glomerulonephritis contributing to further scarring. However, we failed to observe such a deleterious the tubulointerstitium after chronic treatment for 28 days. The inhibition of early apoptosis in the glomeruli may effect in our acute experiment, which may be hidden by the direct effect of B-D-FMK on inflammation. In lead to the reduction of secondary inflammation that addition, the resolution of acute glomerulonephritis may flammation may provide a microenvironment that favors the development of apoptosis. Apoptosis and inflamma-also depend on the migration of inflammatory cells out of the glomeruli upon completion of their task [46] . tion may share so far-unknown upstream molecular mediating mechanisms. The caspase inhibition by B-D-FMK may have had a direct effect on inflammation. There was a reduction of As we demonstrated previously, renal apoptosis and inflammation are associated with tubular atrophy and ED-1ϩ cells early in the glomeruli and tubulointerstitium, and late in the tubulointerstitium. This may result renal fibrosis [7, 29] . It has been revealed that the swift uptake and degradation of apoptotic cells by phagocytes from the reduction of apoptosis as we postulated above. In addition, the decrease of inflammatory cell infiltration leads to a very short half-life for apoptotic cells [3] . Thus, the changes in the small numbers of detectable apoptotic may be linked to the reduction of inflammatory mediators such as IL-1␤. B-D-FMK is a broad-spectrum inhibi-cells may mask a higher rate of apoptosis and result in a significant loss of renal cell mass. Therefore, the inhibition tor of activated caspases, including not only caspase-3 but also caspase-1. Apart from a functional role on apoptosis of renal cell apoptosis and inflammation, in particular, late tubular cell apoptosis and interstitial inflammation, [47], caspase-1, also referred to as ICE, is associated with the activation of IL-1. However, we did not show by B-D-FMK could be helpful to preserve renal parenchymal cells and renal function. The reduction in apopto-a significant change in caspase-1 activity and its active protein in our study, but the precursor of caspase-1 was sis and inflammation was associated with the improvement of proteinuria and renal morphology, including decreased in chronic NTN kidneys and increased again after treatment with B-D-FMK. These may reveal that glomerular sclerosis, tubular atrophy, and tubulointerstitial fibrosis. The reduction in interstitial fibrosis was sup-there was a continuous activation and consumption of caspase-1 simultaneously during time course, which ported by the reduction of collagen I, III, and IV mRNA expression in the chronic study group. There was a statis-would have led to a continuous cleavage of the caspase-1 precursor and kept a stable overall level of active cas-tically significant improvement in renal cellular apoptosis, inflammation, and fibrosis with both acute and chronic pase-1 in the NTN kidneys. This continuous consumption of active caspase-1 may have been involved in the pro-administration of the pan caspase inhibitor. However, we are aware that there is variation between animals cessing of IL-1␤. Furthermore, IL-1␤ active and precursor subunits were significantly increased in both groups and that this kind of treatment partially halted but did not completely stop the progression of renal scarring. of untreated NTN kidneys and reduced by B-D-FMK treatment, although this only reached significance in the Further, we failed to observe a satisfactory improvement in serum creatinine level. Although we did not notice chronic groups. These data found are also consistent with the changes observed in the IL-1␤ mRNA levels.
an obvious toxicity in liver and heart tissues (on hematoxylin and eosin sections, data not shown), the systemic It suggests that the changes of IL-1␤ protein (both active and precursor subunits) and mRNA can occur through toxicity of B-D-FMK needs further investigation. Adjustment in the dose of B-D-FMK may be required to the activation of caspase-1 [42]. IL-1 could in turn contribute to renal inflammation and scarring. Nevertheless, maximize its protective effects and the delivery method needs to be improved to avoid the damage caused by these processes can be inhibited by a pan caspase inhibitor in vivo. In addition, the processing of other inflam-the intrarenal cannulation, although this was contrasted by the vehicle administration to the control animals. matory mediators, such as IL-18 and macrophage inflammatory protein-2 (MIP-2), may require the activation of Apart from caspase, there are another two groups of cysteine proteases, the cathepsin and calpain [50] . Al-caspase-3 [48, 49]. Apoptosis and inflammation could be mutually affected. This was highlighted by the inhibition though cathepsins do not appear to play a role in lethal cell injury, calpain plays an injurious role in ischemic injury to of apoptosis using by ZVAD-FMK and insulin-like growth factor-1 (IGF-1) in renal ischemia/reperfusion, liver, heart, brain and renal ischemia/reperfusion [50, 51] . Calpain activation has been associated with the down-which prevented the associated inflammation [25] . In-regulation and cleavage of calpastatin, a calpain inhibi-REFERENCES tor, by caspase-3 [50] . The relationship between caspase-3 trophiles that are specific enough that they would not 
